Monica Reddy Muppidi, MD & Saby George, MD

Unspecific immunotherapy with interleukin-2 (IL-2) and interferon-alpha was regarded as the first effective therapy in patients with RCC, leading to remarkable clinical benefit in attaining durable complete responses.